- •The differences in DFS between left and right colorectal tumors were investigated in patients recruited to the SCOT study.
- •Right sided colorectal tumors have a worse DFS compared to left sided tumors.
- •Tumor sidedness did not impact upon outcomes for 3 months versus 6 months adjuvant oxaliplatin based chemotherapy.
Patients with loco-regional right-sided colorectal tumors have a worse overall survival (OS). Here we investigate the difference in disease free survival (DFS) between colorectal patients with right and left sided tumors in the SCOT study.
The SCOT study showed 3-months of oxaliplatin-containing adjuvant chemotherapy (OxFp) is non-inferior to 6-months for patients with stage III and high-risk stage II colorectal cancer. We divided the cohort into patients with left and right sided tumors, and evaluated the effect on DFS and the principle 3 versus 6-months analysis.
6088 patients with Stage III/high risk Stage II colorectal cancers were randomized between 27th March 2008 and 29th November 2013 from 244 centers internationally. In February 2017 (3-years FU) information on sidedness was available for 3309 patients (1238 R-sided, 2071 L-sided). Patients with right-sided tumors had a significantly worse DFS (3-year DFS right: 73.3% (se = 1.3%), left: 80.2% (se = 0.9%) HR 1.423 (95% CI 1.237-1.637; P < .0001). Adjusting for T and N-stage reduced the HR to 1.230 (95% CI 1.066-1.420, P = .005). The data did not suggest that sidedness affected the impact of chemotherapy duration on 3-year DFS (R: HR 1.024 [0.831-1.261], L: HR 0.944 [0.783-1.139]). Test for heterogeneity, P = .571. Further sub-set analysis was limited due to cohort size.
This is the first study to show that unselected patients with right-sided tumors had a worse DFS compared to left-sided tumors. Tumor sidedness did not impact upon the 3-months versus 6-months comparison in SCOT.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Clinical Colorectal Cancer
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.Lancet Oncol. 2018; 19: 562-578https://doi.org/10.1016/S1470-2045(18)30093-7
- SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer.Br J Cancer. 2018; 119: 1332-1338https://doi.org/10.1038/s41416-018-0319-z
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.N Engl J Med. 2018; 378: 1177-1188https://doi.org/10.1056/nejmoa1713709
- Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials.Lancet Oncol. 2020; 21: 1620-1629https://doi.org/10.1016/S1470-2045(20)30527-1
- Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes.HHS Public Access. 2020; : 69-80https://doi.org/10.1016/j.ejca.2017.07.016
- The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials.Eur J Cancer. 2017; 70: 87-98https://doi.org/10.1016/j.ejca.2016.10.007
- Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.Ann Oncol. 2017; 28: 1713-1729https://doi.org/10.1093/annonc/mdx175
- Controlling the false discovery rate - a practical and powerful approach to multiple testing.J R Stat Soc. 1995; 57: 289-300https://doi.org/10.2307/2346101
- The worse prognosis of right-sided compared with left-sided colon Cancers: a systematic review and meta-analysis.J Gastrointest Surg. 2016; 20: 648-655https://doi.org/10.1007/s11605-015-3026-6
- Does the primary site of colorectal cancer impact outcomes for patients with metastatic disease?.Cancer. 2015; 121: 830-835https://doi.org/10.1002/cncr.29129
- Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: Results from two randomized first-line panitumumab studies.Ann Oncol. 2017; 28: 1862-1868https://doi.org/10.1093/annonc/mdx119
- Primary tumor location in colorectal Cancer: comparison of right- and left-sided colorectal Cancer characteristics for the interventional radiologist.Cardiovasc Intervent Radiol. 2018; 41: 1819-1825https://doi.org/10.1007/s00270-018-2014-0
- The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials.Eur J Cancer. 2019; 111: 1-7https://doi.org/10.1016/j.ejca.2019.01.020
- Prognostic survival associated with left-sided vs right-sided colon Cancer a systematic review and meta-analysis.JAMA Oncol. 2017; 3: 211-219https://doi.org/10.1001/jamaoncol.2016.4227
- Adjuvant Chemotherapy for stage II right- and left-sided colon Cancer: analysis of SEER-medicare data.Ann Surg Oncol. 2015; 21: 1781-1791https://doi.org/10.1245/s10434-014-3631-8.Adjuvant
- Sidedness is prognostic in locoregional colon cancer: an analysis of 9509 Australian patients.BMC Cancer. 2017; 17: 1-9https://doi.org/10.1186/s12885-017-3255-z
Published online: February 21, 2023
Accepted: February 10, 2023
Received in revised form: February 7, 2023
Received: March 21, 2022
Publication stageIn Press Journal Pre-Proof
© 2023 Published by Elsevier Inc.